{"transactions":[{"id":1267635,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-02-14T16:08:16.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":650000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027 and February 12, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date."}],"balance_after":1140980,"source":{"system":"sec-edgar","filing":"0001628280-25-005696","document":"wk-form4_1739567286.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828025005696/wk-form4_1739567286.xml","form_type":"4"}},{"id":1294596,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-01-27T18:15:24.000Z","date":"2025-01-24","kind":"sale","planned":false,"acquired":false,"shares":22258,"price":0.4535,"value":10094.003,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.4472 to $0.47, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":490980,"source":{"system":"sec-edgar","filing":"0001628280-25-002706","document":"wk-form4_1738019716.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828025002706/wk-form4_1738019716.xml","form_type":"4"}},{"id":1294595,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-01-27T18:15:24.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":61178,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurred upon the acceptance by the European Medicines Agency of the Issuer's Marketing Authorization Application for mavorixafor for the treatment of WHIM syndrome."}],"balance_after":513238,"source":{"system":"sec-edgar","filing":"0001628280-25-002706","document":"wk-form4_1738019716.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828025002706/wk-form4_1738019716.xml","form_type":"4"}},{"id":1389424,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-10-08T16:44:13.000Z","date":"2024-10-07","kind":"sale","planned":false,"acquired":false,"shares":67695,"price":0.5662,"value":38328.909,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These transactions were made pursuant to a rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.55  to $0.6043, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":452060,"source":{"system":"sec-edgar","filing":"0001628280-24-042542","document":"wk-form4_1728420247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828024042542/wk-form4_1728420247.xml","form_type":"4"}},{"id":1389423,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-10-08T16:44:13.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":230645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition."}],"balance_after":519755,"source":{"system":"sec-edgar","filing":"0001628280-24-042542","document":"wk-form4_1728420247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828024042542/wk-form4_1728420247.xml","form_type":"4"}},{"id":1409886,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-09-11T16:01:29.000Z","date":"2024-09-09","kind":"sale","planned":false,"acquired":false,"shares":2642,"price":0.6577,"value":1737.6434,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.6548 to $0.6646, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award."}],"balance_after":289110,"source":{"system":"sec-edgar","filing":"0001628280-24-040128","document":"wk-form4_1726084882.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828024040128/wk-form4_1726084882.xml","form_type":"4"}},{"id":1584529,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-03-11T17:19:38.000Z","date":"2024-03-11","kind":"sale","planned":false,"acquired":false,"shares":15409,"price":0.882,"value":13590.738,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.863 to $0.91, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award."}],"balance_after":291752,"source":{"system":"sec-edgar","filing":"0001628280-24-010278","document":"wk-form4_1710191967.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828024010278/wk-form4_1710191967.xml","form_type":"4"}},{"id":1638589,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Appreciation Right","published_at":"2024-02-16T17:09:45.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":428248,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of February 13, 2024, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date."}],"balance_after":428248,"derivative":{"exercise_price":0.921,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":428248},"source":{"system":"sec-edgar","filing":"0001628280-24-005383","document":"wk-form4_1708121369.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828024005383/wk-form4_1708121369.xml","form_type":"4"}},{"id":1649550,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-02-12T17:23:55.000Z","date":"2024-02-12","kind":"sale","planned":false,"acquired":false,"shares":3683,"price":1.007,"value":3708.781,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.98 to $1.04, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award."}],"balance_after":307161,"source":{"system":"sec-edgar","filing":"0001628280-24-004288","document":"wk-form4_1707776621.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828024004288/wk-form4_1707776621.xml","form_type":"4"}},{"id":1750031,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-11-03T16:40:51.000Z","date":"2023-11-01","kind":"sale","planned":true,"acquired":false,"shares":67695,"price":0.73,"value":49417.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 2, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6839 to $0.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award"}],"balance_after":310844,"source":{"system":"sec-edgar","filing":"0001628280-23-036757","document":"wk-form4_1699044035.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828023036757/wk-form4_1699044035.xml","form_type":"4"}},{"id":1751484,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-11-02T16:55:34.000Z","date":"2023-10-31","kind":"grant","planned":false,"acquired":true,"shares":230645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for mavorixafor."}],"balance_after":378539,"source":{"system":"sec-edgar","filing":"0001628280-23-036459","document":"wk-form4_1698958524.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828023036459/wk-form4_1698958524.xml","form_type":"4"}},{"id":1783098,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-09-12T16:04:56.000Z","date":"2023-09-08","kind":"sale","planned":false,"acquired":false,"shares":2642,"price":1.249,"value":3299.858,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.22 to $1.255, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Of the shares of common stock reported, 74,046 shares represent restricted stock units."}],"balance_after":147894,"source":{"system":"sec-edgar","filing":"0001628280-23-032065","document":"wk-form4_1694549085.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828023032065/wk-form4_1694549085.xml","form_type":"4"}},{"id":1836831,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-07-05T16:05:04.000Z","date":"2023-06-30","kind":"sale","planned":false,"acquired":false,"shares":464,"price":1.89,"value":876.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.84 to $1.96, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Of the shares of common stock reported, 83,046 shares represent restricted stock units."}],"balance_after":150536,"source":{"system":"sec-edgar","filing":"0001628280-23-024229","document":"wk-form4_1688587495.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828023024229/wk-form4_1688587495.xml","form_type":"4"}},{"id":1844395,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-06-26T16:15:35.000Z","date":"2023-06-23","kind":"sale","planned":false,"acquired":false,"shares":857,"price":1.93,"value":1654.01,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.90  to $1.96, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Of the shares of common stock reported, 84,624 shares represent restricted stock units."}],"balance_after":151000,"source":{"system":"sec-edgar","filing":"0001628280-23-023445","document":"wk-form4_1687810523.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828023023445/wk-form4_1687810523.xml","form_type":"4"}},{"id":1852691,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-06-16T16:24:23.000Z","date":"2023-06-15","kind":"sale","planned":false,"acquired":false,"shares":857,"price":2.23,"value":1911.11,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $2.16 to $2.39, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Of the shares of common stock reported, 87,542 shares represent restricted stock units."}],"balance_after":151857,"source":{"system":"sec-edgar","filing":"0001628280-23-022480","document":"wk-form4_1686947049.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828023022480/wk-form4_1686947049.xml","form_type":"4"}},{"id":1957017,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-03-13T16:52:32.000Z","date":"2023-03-10","kind":"sale","acquired":false,"shares":18192,"price":0.84,"value":15281.28,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $0.82 to $0.89, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Of the shares of common stock reported, 90,458 shares represent restricted stock units."}],"balance_after":152714,"source":{"system":"sec-edgar","filing":"0001628280-23-007724","document":"wf-form4_167874073622856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828023007724/wf-form4_167874073622856.xml","form_type":"4"}},{"id":2013804,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-02-15T17:13:24.000Z","date":"2023-02-13","kind":"sale","acquired":false,"shares":4348,"price":0.93,"value":4043.64,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $0.92 to $0.98, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Of the shares of common stock reported, 142,958 shares represent restricted stock units."}],"balance_after":170906,"source":{"system":"sec-edgar","filing":"0001628280-23-003758","document":"wf-form4_167649918418679.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828023003758/wf-form4_167649918418679.xml","form_type":"4"}},{"id":2121331,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Appreciation Right","published_at":"2022-11-09T16:23:26.000Z","date":"2022-11-07","kind":"grant","acquired":true,"shares":1350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of November 7, 2022, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date."}],"balance_after":1350000,"derivative":{"exercise_price":1.8,"expiration_date":"2032-11-07","underlying":"Common Stock","underlying_shares":1350000},"source":{"system":"sec-edgar","filing":"0001628280-22-029265","document":"wf-form4_166802896920270.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828022029265/wf-form4_166802896920270.xml","form_type":"4"}},{"id":2178469,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-08-19T13:07:10.000Z","date":"2022-08-17","kind":"sale","acquired":false,"shares":1713,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.150 to $1.215, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Of the shares of common stock reported, 164,504 shares represent unvested restricted stock units."}],"balance_after":177896,"source":{"system":"sec-edgar","filing":"0001628280-22-023325","document":"wf-form4_166092881804874.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828022023325/wf-form4_166092881804874.xml","form_type":"4"}},{"id":2217504,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-07-01T16:56:49.000Z","date":"2022-06-30","kind":"sale","acquired":false,"shares":1578,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $0.88 to $0.92, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Of the shares of common stock reported, 170,338 shares represent unvested restricted stock units."}],"balance_after":179609,"source":{"system":"sec-edgar","filing":"0001628280-22-018397","document":"wf-form4_165670899460807.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828022018397/wf-form4_165670899460807.xml","form_type":"4"}},{"id":2221389,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-06-27T16:09:20.000Z","date":"2022-06-24","kind":"sale","acquired":false,"shares":856,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.06 to $1.11, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Of the shares of common stock reported, 171,916 shares represent unvested restricted stock units."}],"balance_after":181187,"source":{"system":"sec-edgar","filing":"0001628280-22-018044","document":"wf-form4_165636053048715.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828022018044/wf-form4_165636053048715.xml","form_type":"4"}},{"id":2228304,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-06-17T16:21:40.000Z","date":"2022-06-16","kind":"sale","acquired":false,"shares":856,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.03 to $1.12 inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Of the shares of common stock reported, 174,832 shares represent unvested restricted stock units."}],"balance_after":182043,"source":{"system":"sec-edgar","filing":"0001628280-22-017435","document":"wf-form4_165549727289558.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828022017435/wf-form4_165549727289558.xml","form_type":"4"}},{"id":2365868,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-03-01T16:16:25.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in two equal annual installments on March 1, 2023 and March 1, 2024, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Of the shares of common stock reported, 177,748 shares represent unvested restricted stock units."}],"balance_after":182899,"source":{"system":"sec-edgar","filing":"0001628280-22-004518","document":"wf-form4_164616936069234.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828022004518/wf-form4_164616936069234.xml","form_type":"4"}},{"id":2398572,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-02-14T16:22:02.000Z","date":"2022-02-11","kind":"sale","acquired":false,"shares":12545,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.52 to $1.74, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Of the shares of common stock reported, 72,748 shares represent unvested restricted stock units."}],"balance_after":77899,"source":{"system":"sec-edgar","filing":"0001628280-22-002508","document":"wf-form4_164487367680982.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828022002508/wf-form4_164487367680982.xml","form_type":"4"}},{"id":2573429,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-09-10T16:10:06.000Z","date":"2021-09-08","kind":"grant","acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units issued to the Reporting Person.  Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer and has no expiration date. One third of the shares will vest on each of September 8, 2022, September 8, 2023 and September 8, 2024, respectively, subject to the Reporting Person providing continuous service to the Issuer on such dates."}],"balance_after":90444,"source":{"system":"sec-edgar","filing":"0001628280-21-018385","document":"wf-form4_163130459114894.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828021018385/wf-form4_163130459114894.xml","form_type":"4"}}]}